Thomas A. Fey

1.1k total citations
24 papers, 422 citations indexed

About

Thomas A. Fey is a scholar working on Molecular Biology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Thomas A. Fey has authored 24 papers receiving a total of 422 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 7 papers in Immunology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Thomas A. Fey's work include Signaling Pathways in Disease (5 papers), Urinary Bladder and Prostate Research (4 papers) and Nitric Oxide and Endothelin Effects (3 papers). Thomas A. Fey is often cited by papers focused on Signaling Pathways in Disease (5 papers), Urinary Bladder and Prostate Research (4 papers) and Nitric Oxide and Endothelin Effects (3 papers). Thomas A. Fey collaborates with scholars based in United States, United Kingdom and Germany. Thomas A. Fey's co-authors include Karl W. Mollison, R. A. Krause, Michael E. Brune, Włodek Mandecki, Rohinton Edalji, Erik R. P. Zuiderweg, Richard G. Conway, L.S. Miller, Murali Gopalakrishnan and Michael J. Coghlan and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The FASEB Journal and Annals of the New York Academy of Sciences.

In The Last Decade

Thomas A. Fey

24 papers receiving 401 citations

Peers

Countries citing papers authored by Thomas A. Fey

Since Specialization

Citations

This map shows the geographic impact of Thomas A. Fey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas A. Fey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas A. Fey more than expected).

Fields of papers citing papers by Thomas A. Fey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas A. Fey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas A. Fey. The network helps show where Thomas A. Fey may publish in the future.

Co-authorship network of co-authors of Thomas A. Fey

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas A. Fey. A scholar is included among the top collaborators of Thomas A. Fey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas A. Fey. Thomas A. Fey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pharmacological Properties and Procognitive Effects of ABT-288, a Potent and Selective Histamine H3 Receptor Antagonist 2012 ·Journal of Pharmacology and Experimental Therapeutics ·Timothy A. Esbenshade, Kaitlin E. Browman, Thomas R. Miller, Kathleen M. Krueger, (unknown), Min Zhang, Gerard B. Fox, Lynne E. Rueter, Holly M. Robb, Richard J. Radek, Karla Drescher, Thomas A. Fey, Robert S. Bitner, Kennan C. Marsh, James S. Polakowski, Chen Zhao, Marlon Cowart, Arthur A. Hancock, James P. Sullivan, Jorge D. Brioni	38
2	Zotarolimus, a Novel Sirolimus Analogue With Potent Anti-proliferative Activity on Coronary Smooth Muscle Cells and Reduced Potential for Systemic Immunosuppression 2007 ·Journal of Cardiovascular Pharmacology ·Yung‐Wu Chen, Morey L. Smith, Michael P. Sheets, (unknown), James M. Trevillyan, Sandra E. Burke, (unknown), (unknown), Rolf Wagner, Joy Bauch, Kennan Marsh, Thomas A. Fey, Gin C. Hsieh, Donna M. Gauvin, Karl W. Mollison, George W. Carter, Stevan W. Djurić	55
3	Pharmacological characterization of urinary bladder smooth muscle contractility following partial bladder outlet obstruction in pigs 2006 ·European Journal of Pharmacology ·Ivan Milicic, Steven A. Buckner, A.V. Daza, Michael J. Coghlan, Thomas A. Fey, Michael E. Brune, Murali Gopalakrishnan	14
4	Distinctions and contradistinctions between antiobesity histamine H3 receptor (H3R) antagonists compared to cognition-enhancing H3 receptor antagonists 2006 ·Inflammation Research ·Timothy A. Esbenshade, Arthur A. Hancock, Robert S. Bitner, K. M. Krueger, Sebastian Otte, Arthur L. Nikkel, Thomas A. Fey, Eugene N. Bush, Robert Dickinson, Robin Shapiro, (unknown), Brian A. Droz, (unknown), Peer B. Jacobson, M. D. Cowart	11
5	Chronic Treatment with Either Dexfenfluramine or Sibutramine in Diet-Switched Diet-Induced Obese Mice 2006 ·Endocrine ·Eugene N. Bush, Robin Shapiro, Michael E. Brune, (unknown), Brian A. Droz, Thomas A. Fey, Emily Lin, Peer B. Jacobson	9
6	Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy 2005 ·Inflammation Research ·Arthur A. Hancock, (unknown), Thomas A. Fey, Eugene N. Bush, (unknown), Ted R. Miller, K. M. Krueger, John K. Pratt, M. D. Cowart, Robert Dickinson, Robin Shapiro, (unknown), Brian A. Droz, (unknown), G. Krishna, (unknown), Timothy A. Esbenshade, Peer B. Jacobson	13
7	Differential effects of Vitamin D analogs on bone formation and resorption 2005 ·The Journal of Steroid Biochemistry and Molecular Biology ·Masaki Nakane, Thomas A. Fey, (unknown), Junli Ma, Michael E. Brune, Yan Chun Li, J. Ruth Wu-Wong	29
8	In vitro and in vivo characterization of a novel naphthylamide ATP‐sensitive K⁺ channel opener, A‐151892 2004 ·British Journal of Pharmacology ·Murali Gopalakrishnan, Steven A. Buckner, Char‐Chang Shieh, Thomas A. Fey, (unknown), Kristi L. Whiteaker, Rachel Davis‐Taber, Ivan Milicic, A.V. Daza, Victoria Scott, Neil A. Castle, David Printzenhoff, (unknown), Sean Turner, William A. Carroll, James P. Sullivan, Michael J. Coghlan, Michael E. Brune	8
9	Effects of ATP‐sensitive K⁺ channel openers and tolterodine on involuntary bladder contractions in a pig model of partial bladder outlet obstruction 2003 ·Neurourology and Urodynamics ·Thomas A. Fey, Murali Gopalakrishnan, (unknown), (unknown), Jorge D. Brioni, James P. Sullivan, Michael J. Coghlan, Michael E. Brune	18
10	(−)-(9 S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4 H)-one 1,1-Dioxide (A-278637): A Novel ATP-Sensitive Potassium Channel Opener Efficacious in Suppressing Urinary Bladder Contractions. II. In Vivo Characterization 2002 ·Journal of Pharmacology and Experimental Therapeutics ·Michael E. Brune, Thomas A. Fey, Jorge D. Brioni, James P. Sullivan, Michael B. Williams, William A. Carroll, Michael J. Coghlan, Murali Gopalakrishnan	26
11	A Macrolactam Inhibitor of T Helper Type 1 and T Helper Type 2 Cytokine Biosynthesis for Topical Treatment of Inflammatory Skin Diseases1 1999 ·Journal of Investigative Dermatology ·Karl W. Mollison, Thomas A. Fey, Donna M. Gauvin, (unknown), Michael P. Sheets, Morey L. Smith, (unknown), Nikolaos M. Nikolaidis, Benjamin C. Lane, James M. Trevillyan, George W. Carter, (unknown), (unknown), (unknown), John Cannon, Kennan C. Marsh, Jay R. Luly	10
12	Ex VivoAssessment of Immunosuppression in Undiluted Whole Blood from Pigs Dosed with Tacrolimus (FK506) 1999 ·Clinical Immunology ·Yung‐Wu Chen, Morey L. Smith, Michael P. Sheets, Stephen J. Ballaron, James M. Trevillyan, Thomas A. Fey, Donna M. Gauvin, (unknown), (unknown), Gin C. Hsieh, Joy Bauch, Kennan C. Marsh, George Carter, Jay R. Luly, Stevan W. Djurić, Karl W. Mollison	3
13	Nephrotoxicity studies of the immunosuppressants tacrolimus (FK506) and ascomycin in rat models 1998 ·Toxicology ·Karl W. Mollison, Thomas A. Fey, R. A. Krause, (unknown), (unknown), Patrick K. Cusick, Gin C. Hsieh, Jay R. Luly	15
14	Improved Methods for Transplanting Split-heart Neonatal Cardiac Grafts Into the Ear Pinna of Mice and Rats 1998 ·Journal of Pharmacological and Toxicological Methods ·Thomas A. Fey, R. A. Krause, Gin C. Hsieh, (unknown), (unknown), (unknown), Jay R. Luly, Karl W. Mollison	18
15	Discovery of Less Nephrotoxic FK506 Analogs and Determining Immunophilin Dependence of Immunosuppressant Nephrotoxicity with a Novel Single-Dose Rat Cisplatin Potentiation Assay 1997 ·Journal of Pharmacology and Experimental Therapeutics ·Karl W. Mollison, Thomas A. Fey, R. A. Krause, (unknown), (unknown), J. Brandt, Megumi Kawai, Rolf Wagner, Gin C. Hsieh, Jay R. Luly	6
16	Comparison of FK‐506, Rapamycin, Ascomycin, and Cyclosporine in Mouse Models of Host‐versus‐Graft Disease and Heterotopic Heart Transplantation 1993 ·Annals of the New York Academy of Sciences ·Karl W. Mollison, Thomas A. Fey, R. A. Krause, Veena A. Thomas, Ajita Mehta, Jay R. Luly	8
17	Heterogeneity in chemokinetic and enzyme release efficacy of c5a analogs across multiple species 1992 ·The FASEB Journal ·Thomas A. Fey, Karl W. Mollison, R. A. Krause, (unknown), Paul E. Wiedeman, Misako Kawai, B. G. Lane, Jay R. Luly, (unknown)	1
18	Dunaimycins, a new complex of spiroketal 24-membered macrolides with immunosuppressive activity. III. Immunosuppressive activities of dunaimycins. 1991 ·The Journal of Antibiotics ·Neal S. Burres, USHA PREMACHANDRAN, (unknown), Sue Swanson, Karl W. Mollison, Thomas A. Fey, R. A. Krause, Valerie A. Thomas, Ben Lane, Loan Miller, James B. McAlpine	12
19	Identification of receptor-binding residues in the inflammatory complement protein C5a by site-directed mutagenesis. 1989 ·Proceedings of the National Academy of Sciences ·Karl W. Mollison, Włodek Mandecki, Erik R. P. Zuiderweg, (unknown), Thomas A. Fey, R. A. Krause, Richard G. Conway, L.S. Miller, Rohinton Edalji, (unknown)	97
20	High-level C5a gene expression and recovery of recombinant human C5a fromEscherichia coli 1987 ·Inflammation Research ·Karl W. Mollison, Thomas A. Fey, R. A. Krause, Włodek Mandecki, Jeffrey L. Fox, (unknown)	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact